Trials / Terminated
TerminatedNCT00415246
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
A Phase III, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of a Subcutaneous Four Months Sustained-release Formulation of Triptorelin, a Gonadotrophin Releasing Hormone Analogue in Patients With Prostate Cancer
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Ipsen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To identify the proportion of patients remaining medically castrated (testosterone level \< 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study) |
Timeline
- Start date
- 2006-11-01
- Completion
- 2007-10-01
- First posted
- 2006-12-22
- Last updated
- 2019-11-22
Locations
31 sites across 8 countries: Belgium, France, Latvia, Lithuania, Poland, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00415246. Inclusion in this directory is not an endorsement.